Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial

Clinical trial NCT06438627 · RECRUITING

Trial details

NCT number: NCT06438627
Sponsor: XIANG YANQUN
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Nasopharyngeal Carcinoma

Start date: 2024-05-30
Primary completion: 2026-05-30
Enrollment: 164

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.